RNXT
RenovoRx, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+2/100
Last price
1.39
▼ 0.08 (5.44%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.47
Day high
1.57
Day low
1.37
Volume
621.07K
Market cap
$62.73M
P/E (TTM)
—
52W range
0.70 – 2.59
Trailing performance
Returnvs SPY
1W
-11.46%
-13.4%
1M
-41.84%
-43.0%
3M
+54.44%
+49.9%
6M
+54.44%
+36.3%
YTD
+65.48%
+51.2%
1Y
+5.30%
-11.1%
3Y
+4.51%
-77.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RNXT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.62M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | VOLL MARK Chief Financial Officer |
STOCK | 80.00K | $0 | Direct |
| May 19, 26 | VOLL MARK Chief Financial Officer |
BUY | 25.00K | $19.69K | Direct |
| Apr 2, 26 | VOLL MARK Chief Financial Officer |
STOCK | 80.00K | $0 | Direct |
| Mar 25, 26 | VOLL MARK Chief Financial Officer |
STOCK | 12.38K | $0 | Direct |
| Mar 20, 26 | VOLL MARK Chief Financial Officer |
BUY | 97.20K | $97.20K | Indirect |
| Mar 20, 26 | MARTON LAURENCE Director |
BUY | 9.72K | $9.72K | Indirect |
| Mar 20, 26 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 24.30K | $24.30K | Indirect |
| Jan 21, 26 | AGAH RAMTIN M.D. Officer and Director |
BUY | 10.00K | $9.97K | Direct |
| Dec 31, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 9.79K | $8.42K | Direct |
| Dec 30, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 205 | $169 | Direct |
| Dec 18, 25 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 5.00K | $4.51K | Direct |
| Dec 17, 25 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 5.00K | $4.26K | Direct |
| Dec 16, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 12.00K | $10.20K | Direct |
| Dec 5, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 10.00K | $9.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGAH RAMTIN M.D. |
Officer and Director | 798.46K | Purchase |
BAGAI SHAUN R. |
Chief Executive Officer | — | Purchase |
KOCAK RONALD B. CPA |
Officer | 12.60K | Purchase |
MARTON LAURENCE |
Director | — | Purchase |
VOLL MARK |
Chief Financial Officer | 319.58K | Stock Award(Grant) |
Fundamentals
Market cap$62.73M
Enterprise value$53.64M
Revenue (TTM)$1.98M
Gross profit$1.67M
EBITDA$-13.03M
Net income$-12.29M
EPS (TTM)$-0.31
Free cash flow$-6.65M
Total cash$9.48M
Total debt$390.00K
Book value / share$0.20
Shares outstanding45.13M
Float39.17M
Short % of float1.54%
Dividend yield0.00%
Beta (5Y)0.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.58
PEG ratio—
Price / sales—
Price / book6.98
EV / revenue27.15
EV / EBITDA-4.12
Gross margin84.41%
Operating margin-368.43%
Profit margin0.00%
Return on equity-125.23%
Return on assets-64.90%
Debt / equity4.34
Current ratio5.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.12M | $43.00K | $0 | $0 | +2,511.6% |
| Operating revenue | $1.12M | $43.00K | $0 | $0 | +2,511.6% |
| Cost of revenue | $327.00K | $0 | $0 | — | — |
| Gross profit | $796.00K | $43.00K | $0 | — | +1,751.2% |
| Research & development | $6.27M | $6.03M | $5.67M | $4.30M | +4.0% |
| Selling, general & admin | $7.04M | $4.99M | $5.73M | $5.65M | +41.1% |
| Total operating expense | $13.31M | $11.01M | $11.40M | $9.95M | +20.8% |
| Operating income | -$12.51M | -$10.97M | -$11.40M | -$9.95M | -14.0% |
| Net interest income | $427.00K | $384.00K | -$545.00K | $57.00K | +11.2% |
| Pre-tax income | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -26.7% |
| Net income | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -26.7% |
| Net income to common | -$11.17M | -$8.81M | -$10.23M | -$9.89M | -26.7% |
| Basic EPS | -0.32 | -0.40 | -0.99 | -1.09 | +20.0% |
| Diluted EPS | -0.32 | -0.40 | -0.99 | -1.09 | +20.0% |
| EBIT | -$12.51M | -$10.97M | -$11.40M | -$9.95M | -14.0% |
| EBITDA | -$12.51M | -$10.97M | -$11.40M | -$9.94M | -14.0% |
| Basic shares | 35.33M | 22.27M | 10.29M | 9.05M | +58.6% |
| Diluted shares | 35.33M | 22.27M | 10.29M | 9.05M | +58.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.02M | $7.15M | $1.17M | $4.39M | -1.8% |
| Cash & short-term investments | $7.02M | $7.15M | $1.17M | $6.44M | -1.8% |
| Accounts receivable | $139.00K | $43.00K | $0 | — | +223.3% |
| Inventory | $189.00K | $0 | — | — | — |
| Total current assets | $7.89M | $7.83M | $1.47M | $7.26M | +0.8% |
| Property, plant & equipment | $202.00K | $290.00K | $0 | $0 | -30.3% |
| Total assets | $8.10M | $8.12M | $1.47M | $7.26M | -0.3% |
| Total current liabilities | $1.96M | $1.91M | $1.18M | $1.10M | +2.8% |
| Total debt | $212.00K | $278.00K | $0 | — | -23.7% |
| Total liabilities | $2.67M | $3.64M | $4.47M | $1.10M | -26.6% |
| Retained earnings | -$61.39M | -$50.22M | -$41.41M | -$31.17M | -22.2% |
| Shareholder equity | $5.42M | $4.48M | -$3.00M | $6.16M | +21.1% |
| Working capital | $5.93M | $5.92M | $291.00K | $6.16M | +0.2% |
| Net tangible assets | $5.42M | $4.48M | -$3.00M | $6.16M | +21.1% |
| Shares issued | 36.61M | 24.03M | 10.69M | 9.10M | +52.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$11.17M | -$8.81M | -$10.23M | -$9.89M | — | -26.7% |
| Depreciation & amortisation | $2.00K | $0 | $0 | $6.00K | — | — |
| Stock-based compensation | $1.27M | $1.17M | $1.08M | $644.00K | — | +7.9% |
| Change in working capital | -$247.00K | $280.00K | $605.00K | $428.00K | — | -188.2% |
| Operating cash flow | -$10.97M | -$9.13M | -$10.26M | -$8.81M | — | -20.3% |
| Capital expenditure | -$2.00K | -$12.00K | — | — | -$15.00K | +83.3% |
| Investing cash flow | -$2.00K | -$12.00K | $2.03M | -$2.03M | — | +83.3% |
| Financing cash flow | $10.85M | $15.12M | $5.01M | $42.00K | — | -28.3% |
| Free cash flow | -$10.97M | -$9.14M | -$10.26M | -$8.81M | — | -20.1% |
| End cash position | $7.02M | $7.15M | $1.17M | $4.39M | — | -1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $909.00K | $563.00K | $238.00K | $266.00K | $422.00K | — | +61.5% |
| Operating revenue | $909.00K | $563.00K | $238.00K | $266.00K | $422.00K | — | +61.5% |
| Cost of revenue | $143.00K | $84.00K | $28.00K | $53.00K | $152.00K | — | +70.2% |
| Gross profit | $766.00K | $479.00K | $210.00K | $213.00K | $270.00K | — | +59.9% |
| Research & development | $1.20M | $1.23M | $1.50M | $1.69M | $1.43M | — | -2.3% |
| Selling, general & admin | $2.92M | $2.72M | $2.23M | $1.73M | $1.52M | — | +7.2% |
| Total operating expense | $4.12M | $3.95M | $3.73M | $3.41M | $2.95M | — | +4.2% |
| Operating income | -$3.35M | -$3.47M | -$3.52M | -$3.20M | -$2.68M | — | +3.5% |
| Net interest income | $90.00K | $45.00K | $75.00K | $113.00K | $133.00K | — | +100.0% |
| Pre-tax income | -$2.91M | -$3.52M | -$2.94M | -$2.91M | -$2.90M | — | +17.3% |
| Net income | -$2.91M | -$3.52M | -$2.94M | -$2.91M | -$2.90M | — | +17.3% |
| Net income to common | -$2.91M | -$3.52M | -$2.94M | -$2.91M | -$2.90M | — | +17.3% |
| Basic EPS | -0.06 | -0.09 | — | -0.08 | -0.08 | -0.08 | +33.3% |
| Diluted EPS | -0.06 | -0.09 | — | -0.08 | -0.08 | -0.08 | +33.3% |
| EBIT | -$3.35M | -$3.47M | -$3.52M | -$3.20M | -$2.68M | — | +3.5% |
| EBITDA | -$3.34M | -$3.47M | -$3.52M | -$3.20M | -$2.68M | — | +3.6% |
| Basic shares | 47.30M | 38.03M | — | 36.65M | 36.58M | 31.40M | +24.4% |
| Diluted shares | 47.30M | 38.03M | — | 36.65M | 36.58M | 31.40M | +24.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.48M | $12.36M | $7.02M | $10.04M | $12.31M | -23.3% |
| Cash & short-term investments | $9.48M | $12.36M | $7.02M | $10.04M | $12.31M | -23.3% |
| Accounts receivable | $480.00K | $280.00K | $139.00K | $169.00K | $363.00K | +71.4% |
| Inventory | $383.00K | $379.00K | $189.00K | $272.00K | — | +1.1% |
| Total current assets | $10.81M | $13.72M | $7.89M | $10.98M | $13.39M | -21.2% |
| Property, plant & equipment | $462.00K | $244.00K | $202.00K | $226.00K | $248.00K | +89.3% |
| Total assets | $11.47M | $13.96M | $8.10M | $11.21M | $13.64M | -17.8% |
| Total current liabilities | $1.88M | $1.92M | $1.96M | $1.88M | $1.56M | -1.9% |
| Total debt | $390.00K | $186.00K | $212.00K | $236.00K | $260.00K | +109.7% |
| Total liabilities | $2.49M | $2.70M | $2.67M | $3.13M | $3.00M | -7.6% |
| Retained earnings | -$67.82M | -$64.91M | -$61.39M | -$58.45M | -$55.53M | -4.5% |
| Shareholder equity | $8.98M | $11.27M | $5.42M | $8.08M | $10.64M | -20.3% |
| Working capital | $8.93M | $11.80M | $5.93M | $9.10M | $11.84M | -24.4% |
| Net tangible assets | $8.98M | $11.27M | $5.42M | $8.08M | $10.64M | -20.3% |
| Shares issued | 45.12M | 45.05M | 36.61M | 36.65M | 36.65M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.91M | -$3.52M | -$2.94M | -$2.91M | -$2.90M | — | +17.3% |
| Depreciation & amortisation | $5.00K | $1.00K | $1.00K | -$1.00K | $1.00K | — | +400.0% |
| Stock-based compensation | $570.00K | $317.00K | $285.00K | $349.00K | $345.00K | — | +79.8% |
| Change in working capital | -$216.00K | -$626.00K | $118.00K | $446.00K | -$123.00K | — | +65.5% |
| Operating cash flow | -$2.87M | -$3.71M | -$3.02M | -$2.27M | -$2.30M | — | +22.7% |
| Capital expenditure | — | — | — | — | — | -$2.00K | — |
| Investing cash flow | -$71.00K | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | $55.00K | $9.05M | $0 | $0 | $34.00K | — | -99.4% |
| Free cash flow | -$2.94M | -$3.71M | -$3.02M | -$2.27M | -$2.30M | — | +20.8% |
| End cash position | $9.48M | $12.36M | $7.02M | $10.04M | $12.31M | — | -23.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.05 | +33.3% |
| Mar 2026 | -0.08 | -0.08 | -4.3% |
| Dec 2025 | -0.08 | -0.08 | 0.0% |
| Sep 2025 | -0.08 | -0.08 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.05 | 2 | $1.06M | +300.2% |
| Next quarter | -0.05 | 2 | $1.34M | +461.3% |
| Current year | -0.27 | 1 | $3.87M | +244.8% |
| Next year | -0.12 | 2 | $11.43M | +195.3% |
Analyst targets & ownership
Mean target$7.13
High target$14.50
Low target$3.00
Implied upside412.59%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders3.60%
Held by institutions20.38%
Institutions holding30
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.56
-11.13% from price
SMA 20
1.65
-15.54% from price
SMA 50
1.51
-7.70% from price
SMA 100
1.20
+15.71% from price
SMA 200
1.07
+29.43% from price
EMA 12
1.57
-11.52% from price
EMA 26
1.60
-13.33% from price
EMA 50
1.51
-7.65% from price
RSI (14)
39.2
Neutral
MACD (12,26,9)
-0.03
Hist -0.05
ATR (14)
0.13
9.20% of price
Realised vol 30D
119.6%
Annualised
Bollinger upper
1.90
20, 2σ
Bollinger lower
1.40
20, 2σ
50 / 200 cross
Golden
1.51 vs 1.07
Trend bias
Above 200
+29.43%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.44
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
119.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-45.3%
Peak to trough
Max drawdown 5Y
-92.9%
Peak to trough
ATR 14
0.13
9.20% of price
Beta (reported)
0.97
5Y monthly, from filing
Short interest
Shares short
673.56K
Prior 674.02K
Change vs prior
-0.1%
Shorts covering
% of float
1.54%
Normal
% of shares out
1.49%
Against total outstanding
Days to cover
0.5
Liquid
Float
39.17M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 28, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 1, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Apr 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 17, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Nov 21, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Aug 25, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 5, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| May 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 28, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Apr 4, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 27, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-20
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-02
Offering Registrations
S-8 · 2026-06-30
Periodic Financial Reports
10-K/A · 2026-05-15
Periodic Financial Reports
10-Q · 2026-05-14
Headlines
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
GlobeNewswire · 6d ago
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
InvestorsHub · 35d ago
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
GlobeNewswire · 35d ago
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
GlobeNewswire · 43d ago
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire · 47d ago
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
GlobeNewswire · 48d ago
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
MarketBeat · 51d ago
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
GuruFocus.com · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.